Lim KB (2017) Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 4:148–151. https://doi.org/10.1016/j.ajur.2017.06.004

Article  PubMed  PubMed Central  Google Scholar 

Creta M, Collà Ruvolo C, Longo N, Mangiapia F, Arcaniolo D, DE Sio M et al (2021) Detrusor overactivity and underactivity: implication for lower urinary tract symptoms related to benign prostate hyperplasia diagnosis and treatment. Minerva Urol Nephrol 73:59–71. https://doi.org/10.23736/S2724-6051.20.03678-4

Article  PubMed  Google Scholar 

Brown CT, van der Meulen J, Mundy AR, O’Flynn E, Emberton M (2004) Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol 46:254–262 discussion 263. https://doi.org/10.1016/j.eururo.2004.02.008

Article  PubMed  Google Scholar 

Sun Y, Peng B, Lei G-L, Wei Q, Yang L (2020) Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Minerva Urol Nefrol 72:13–21. https://doi.org/10.23736/S0393-2249.19.03408-8

Article  PubMed  Google Scholar 

Xie C-Y, Zhu G-B, Wang X-H, Liu X-B (2012) Five-year follow-up results of a randomized controlled trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Yonsei Med J 53:734–741. https://doi.org/10.3349/ymj.2012.53.4.734

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cornu J-N, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C et al (2015) A systematic review and Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from Benign Prostatic obstruction: an update. Eur Urol 67:1066–1096. https://doi.org/10.1016/j.eururo.2014.06.017

Article  PubMed  Google Scholar 

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118–140. https://doi.org/10.1016/j.eururo.2013.03.004

Article  PubMed  Google Scholar 

Nguyen D-D, Li T, Ferreira R, Baker Berjaoui M, Nguyen A-LV, Chughtai B et al (2023) Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: a review of Aquablation, Rezum, and transperineal laser prostate ablation. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-023-00669-z

Article  PubMed  PubMed Central  Google Scholar 

Roehrborn CG, Chin PT, Woo HH (2022) The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction. Prostate Cancer Prostatic Dis 25:79–85. https://doi.org/10.1038/s41391-021-00434-0

Article  PubMed  Google Scholar 

Amparore D, De Cillis S, Schulman C, Kadner G, Fiori C, Porpiglia F (2023) Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. Minerva Urol Nephrol 75:743–751. https://doi.org/10.23736/S2724-6051.23.05322-3

Article  PubMed  Google Scholar 

Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D et al (2021) New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: a systematic review and analysis of comparative outcomes. Eur Urol Open Sci 33:28–41. https://doi.org/10.1016/j.euros.2021.08.009

Article  PubMed  PubMed Central  Google Scholar 

Sibona M, Destefanis P, Vercelli E, Secco S, Gontero P, Cindolo L (2023) Ejaculation physiology and dysfunction after BPH surgery: the role of the new MISTs. Prostate Cancer Prostatic Dis 26:475–482. https://doi.org/10.1038/s41391-023-00686-y

Article  PubMed  Google Scholar 

Cornu J-N, Zantek P, Burtt G, Martin C, Martin A, Springate C et al (2023) Minimally invasive treatments for Benign Prostatic obstruction: a systematic review and network Meta-analysis. Eur Urol 83:534–547. https://doi.org/10.1016/j.eururo.2023.02.028

Article  PubMed  Google Scholar 

Manfredi C, Arcaniolo D, Spatafora P, Crocerossa F, Fusco F, Verze P et al (2022) Emerging minimally invasive transurethral treatments for benign prostatic hyperplasia: a systematic review with meta-analysis of functional outcomes and description of complications. Minerva Urol Nephrol 74:389–399. https://doi.org/10.23736/S2724-6051.21.04530-4

Article  PubMed  Google Scholar 

Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T et al (2022) Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol 29:10960–10968

PubMed  Google Scholar 

Fiori C, Checcucci E, Gilling P, Amparore D, Volpi G, De Cillis S et al (2020) All you need to know about Aquablation procedure for treatment of benign prostatic obstruction. Minerva Urol Nefrol 72:152–161. https://doi.org/10.23736/S0393-2249.20.03654-1

Article  PubMed  Google Scholar 

Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T et al (2019) Randomized Controlled Trial of Aquablation versus Transurethral Resection of the prostate in Benign Prostatic Hyperplasia: one-year outcomes. Urology 125:169–173. https://doi.org/10.1016/j.urology.2018.12.002

Article  PubMed  Google Scholar 

Plante M, Gilling P, Barber N, Bidair M, Anderson P, Sutton M et al (2019) Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU Int 123:651–660. https://doi.org/10.1111/bju.14426

Article  PubMed  Google Scholar 

Oumedjbeur K, Corsi NJ, Bouhadana D, Ibrahim A, Nguyen D-D, Matta I et al (2023) Aquablation versus TURP: 5-year outcomes of the WATER randomized clinical trial for prostate 50–80 mL. Can J Urol 30:11650–11658

PubMed  Google Scholar 

Pimentel MA, Yassaie O, Gilling P (2019) Urodynamic outcomes after Aquablation. Urology 126:165–170. https://doi.org/10.1016/j.urology.2019.01.020

Article  PubMed  Google Scholar 

Bhojani N, Bidair M, Kramolowsky E, Desai M, Doumanian L, Zorn KC et al (2023) Aquablation Therapy in large prostates (80–150 mL) for lower urinary tract symptoms due to Benign Prostatic Hyperplasia: final WATER II 5-Year clinical trial results. J Urol 210:143–153. https://doi.org/10.1097/JU.0000000000003483

Article  PubMed  Google Scholar 

Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae

Article  PubMed  PubMed Central  Google Scholar 

Elterman DS, Foller S, Ubrig B, Kugler A, Misrai V, Porreca A et al (2021) Focal bladder neck cautery associated with low rate of post-aquablation bleeding. Can J Urol 28:10610–10613

PubMed  Google Scholar 

Bach T, Giannakis I, Bachmann A, Fiori C, Gomez-Sancha F, Herrmann TRW et al (2019) Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort. World J Urol 37:1369–1375. https://doi.org/10.1007/s00345-018-2509-y

Article  PubMed  CAS  Google Scholar 

Kasivisvanathan V, Hussain M (2018) Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes. Can J Urol 25:9317–9322

PubMed  Google Scholar 

Nedbal C, Castellani D, De Stefano V, Giulioni C, Nicoletti R, Pirola G et al Will Aquablation be the New Benchmark for Robotic minimally invasive Surgical treatment for Benign Prostatic Hyperplasia? Eur Urol Focus 2023:S2405-4569(23)00293-6. https://doi.org/10.1016/j.euf.2023.12.001